STONY BROOK, NY / ACCESSWIRE / August 19, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced its intention to seek an expansion of the approved intended use of its Lineaâ„¢ Mpox Virus 1.0 Assay (the "Assay") to include the detection of mpox Clade I that is the subject of the World Health Organization's (WHO) 14 August 2024 declaration of a public health emergency of international concern (PHEIC). The Company's internally generated data show that the Assay can detect the genetic sequence of mpox Clade I and is now undertaking validation studies to enable the filing of necessary documentation with the New York State Department of Health (NYSDOH). The Company plans to make its NYSDOH filing as soon as practicable based on the turnaround times for necessary reagents and control materials. No assurance can be given regarding the timing of any NYSDOH approval and whether such approval will ever be granted.
The Assay was approved as a laboratory-developed test for the detection of mpox Clade II (previously monkeypox) by NYSDOH in September 2022. If approved for the testing of Clade I, the Company could provide clinical testing services in its CLEP/CLIA molecular diagnostics laboratory in Stony Brook, N.Y. for mpox Clade I and Clade II on samples originating in New York State and in states that recognize New York's CLEP/CLIA certification for testing.
Laboratory/Test Information
Applied DNA Clinical Labs, LLC ("ADCL") is a NYSDOH CLEP-permitted, Clinical Laboratory Improvement Amendments ("CLIA")-certified clinical laboratory, certified to perform high-complexity testing. The Lineaâ„¢ Mpox Virus 1.0 Assay was developed, and its performance characteristics were determined by ADCL. The Lineaâ„¢ Mpox Virus 1.0 Assay has not been cleared or approved by the U.S. Food and Drug Administration. The Lineaâ„¢ Mpox Virus 1.0 Assay is intended for clinical purposes.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Further, the uncertainties inherent in research and development, future data and analysis, including whether Linea Mpox Virus 1.0 Assay will, if ever, be validated for the detection of mpox Clade I in clinical samples or whether the Linea Mpox Virus 1.0 Assay will, if ever, receive approval from NYSDOH for the detection of mpox Clade I in clinical samples, and/or disruptions in the supply of raw materials and supplies In addition, actual results could differ materially from those projected due to the Company's history of net losses, the unknown demand, revenue and profits, if any, that will result from mpox testing, limited financial resources, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023, and Quarterly Report on Form 10-Q filed on February 8, 2024, May 10, 2024, and August 8, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Contacts:
Applied DNA Sciences
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, [email protected]
Web: www.adnas.com
Twitter: @APDN
###
SOURCE: Applied DNA Sciences, Inc.
View the original press release on accesswire.com
